Lutetium-177: a game changer Theranostic agent

Congress:

ECR 2019

Poster Number:

C-1772

Type:

Educational Exhibit

Keywords:

Oncology, Molecular imaging, Hybrid Imaging, SPECT-CT, SPECT, Nuclear medicine conventional, Radionuclide therapy, Radiation safety, Outcomes analysis, Cancer, Metastases, Education and training

Authors:

M. Vyas, S. Shaikh; Auckland/NZ

DOI:

10.26044/ecr2019/C-1772

DOI-Link:

https://dx.doi.org/10.26044/ecr2019/C-1772

Fig. 1: Image 1

Fig. 2: Image 2

Fig. 3: Image 3

Fig. 4: Image 4

Learning objectives

Understand the evolving theranostic applications of a promising radionuclide Lutetium-177 (Lu177). Review and highlight the role of Lu177 in improving the quality of life for patients affected with Neuroendocrine tumours (NETs) and metastatic castration-resistant prostate cancer (mCRPC).

Background

The ‘theranostic’ term is used when a disease can be diagnosed and treated with the same agent using the same physiological uptake method (Palekar-Shanbhag, Jog, Chogale, & Gaikwad, 2013). The first time the theranostics term was proposed by John Funkhouser (Chief executive officer, PharmaNetics) at the end of the last century. He used this term to define his model of philosophy for diagnostic and therapy techniques (Idée, Louguet, Ballet, & Corot, 2013). Theranostics branch of medicine has an exciting future because it can eliminate additional...

Findings and procedure details

Procedural details: For this report and presentation, various clinical trials conducted under the Neuroendocrine Tumours Therapy Trials (NETTER) and current ongoing trials for the treatment of mCRPC were reviewed. See table 2 for a list of reviewed clinical trials. In addition, research articles reviewed as listed in the reference, were accessed using search tools such as PubMed and Google scholar and relevant keywords (NET clinical trials, PRRT, Lu-177 labelled PSMA-617 outcomes). Characteristics of an ideal theranostic radionucleotide: Ø It must emit gamma and beta radiation...

Conclusion

Lu-177 has shown promising results in the treatment of tumours. Results of multiple clinical studies promise the exciting future and great potential for Lu-177 as a game changer theranostic agent.

Personal information

References

ADDIN EN.REFLIST Alvarez, R. D., Partridge, E. E., & Khazaeli, M. B. (1997). Gynecol. Oncol., 65, 94. Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Plott, G., Austin, M., Kilgore, L., . . . Meredith, R. F. (1997). Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol, 65(1), 94-101. https://doi.org/10.1006/gyno.1996.4577 Banerjee, S., Pillai, M. R. A., & Knapp, F. F. (2015). Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications. Chemical Reviews, 115(8), 2934-2974. https://doi.org/10.1021/cr500171e Bonnema, S. J., & Hegedüs,...